Table 1 Baseline parameters, basic pathology and immunohistochemical markers for 198 patients with periampullary adenocarcinomas

Male : female

102:96

63:63

14:9

22:18

3:6

0.511

Age

67 (30–89)

67 (30–89)

69 (49–83)

65 (36–84)

66 (46–78)

0.137

Distant metastasis (M1)

7 / 4%

4 / 3%

0 / 0%

2 / 5%

1 / 11%

0.448

Neoadjuvant therapy

14 / 7%

13 / 10%

0 / 0%

1 / 3%

0 / 0%

0.126

Resection

PPPD

163

103

19

34

7

0.803

Whipple

23

14

2

5

2

total PE

12

9

2

1

0

PVR

62 / 31%

53 /42%

6 / 26%

2 / 5%

1 / 11%

0.000

Perioperative mortality

7 / 4%

5 / 4%

2 / 9%

0 / 0%

0 / 0%

0.300

Tumor size (mm)

25 (1–320)

27 (1–80)

15 (8–25)

20 (2–320)

40 (22–60)

0.000

Grade G3/4

72 / 37%

48 / 39%

8 / 35%

12 / 31%

4 / 44%

0.785

Stage T3/4

155 / 78%

109 / 87%

18 / 78%

21 / 53%

7 / 78%

0.000

Stage N1/2

132 / 67%

89 / 71%

14 / 61%

24 / 60%

5 / 56%

0.468

Lymph node ratio (LNR)

.09 (0 - .86)

.10 (0 - .86)

.08 (0 - .72)

.07 (0 - .71)

.10 (0 - .28)

0.694

Lymphangiosis (L1)

87 / 44%

60 / 48%

5 / 22%

19 / 48%

3 / 33%

0.116

Hemangiosis (V1)

29 / 15%

22 / 18%

3 / 13%

2 / 5%

2 / 22%

0.237

Perineural invasion (Pn1)

113 / 57%

88 / 70%

12 / 52%

13 / 33%

0 / 0%

0.000

Associated precursor

Adenoma

20 / 10%

1 / 1%

4 / 17%

12 / 30%

3 / 33%

0.000

IPMN

11 / 6%

11 / 9%

0 / 0%

0 / 0%

0 / 0%

0.084

Positive resection margin

51 / 26%

41 / 33%

5 / 22%

3 / 8%

2 / 22%

0.017

Subtype

INT

39 / 20%

11 / 9%

5 / 22%

18 / 45%

5 / 56%

0.000

MIX

12 / 6%

8 / 6%

2 / 9%

2 / 5%

0 / 0%

PB

118 / 16%

89 / 71%

12 / 52%

15 / 38%

2 / 22%

OTH

6 / 3%

5 / 4%

0 / 0%

0 / 0%

1 / 11%

POOR

23 / 12%

13 / 10%

4 / 17%

5 / 13%

1 / 11%

Immunohistochemical Markers

% CK7+

90 (0–100)

90 (0–100)

95 (0–100)

80 (0–100)

0 (0–60)

0.000

% CK20+

0 (0–100)

0 (0–100)

0 (0–100)

10 (0–100)

70 (10–100)

0.000

% nuclear CDX2+

10 (0–100)

0 (0–100)

0 (0–100)

50 (0–100)

95 (60–100)

0.000